

### IN THE SPECIFICATION

Please delete the first full paragraph at page 1, lines 10-24 in its entirety and insert the following:

This application is a Continuation of U.S. Patent Application No. 09/732,169, filed December 6, 2000, ~~now U.S. Patent Application Publication No. 2002/0068049 A1, published June 6, 2002(now abandoned)~~, which is a Continuation of U.S. Patent Application No. 09/151,376, filed September 10, 1998, now U.S. Patent No. 6,676,935, issued January 13, 2004, which is a Continuation-In-Part of U.S. Patent Application No. 08/669,753, filed June 26, 1996, now U.S. Patent No. 5,871,726, issued February 16, 1999, which is a Continuation-In-Part of U.S. Patent Application No. 08/495,034, filed June 27, 1995, now U.S. Patent No. 5,698,443, issued December 16, 1997.

On page 9 of the Specification, please replace lines 3-9, with the following text:

Figure 14 depicts a nucleotide sequence of a carcinoembryonic antigen TRE (SEQ ID NO:54).

Figure 15 depicts a nucleotide sequence of a prostate-specific antigen TRE (SEQ ID NO: 1).

Figure 16 depicts a nucleotide sequence of a human glandular kallikrein TRE (SEQ ID NO:3).

Figure 17 depicts a nucleotide sequence of a mucin TRE.

Figure 18 depicts a nucleotide sequence of a rat probasin TRE (SEQ ID NO: 9).

Figure 19 depicts a nucleotide sequence and translated amino acid sequence of an adenovirus death protein (SEQ ID NO:10 and SEQ ID NO:11, respectively).

Please insert the attached paper copy of the Sequence Listing after the last page of the specification.